Acute chest syndrome of sickle cell disease: New light on an old problem

Current Opinion in Hematology

Volumn 8, Issue 2, 2001, Pages 111-122

  Stuart, Marie J ^a   Setty, B N Yamaja ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE;

ACUTE DISEASE; ARTICLE; BONE MARROW NECROSIS; CLINICAL FEATURE; FAT EMBOLISM; HUMAN; HYPOXIA; INFECTION; MICROCIRCULATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SYNDROME; THORAX DISEASE;

ACUTE DISEASE; ANEMIA, SICKLE CELL; ANIMALS; BACTERIAL INFECTIONS; HUMANS; LUNG DISEASES; NITRIC OXIDE; SYNDROME;

EID: 0035091136     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200103000-00009     Document Type: Article

References (121)

1. "Acute chest syndrome" in adults with sickle cell anemia
2. Acute chest syndrome in sickle cell disease
3. Pneumonia in young children with homozygous sickle cell disease. Risk and clinical features
4. Acute chest syndrome in sickle cell disease. Etiology and clinical correlates
5. Acute chest syndrome in children with sickle cell disease. A retrospective analysis of 100 hospitalized cases
6. Causes of death in sickle cell disease in Jamaica
7. Mortality in sickle celt disease. Life expectancy and risk factors for early death
8. Acute chest syndrome in sickle cell disease. Clinical presentation and course
9. Sickle cell chronic lung disease. Prior morbidity and the risk of pulmonary failure
10. The acute chest syndrome in sickle cell disease: Incidence and risk factors
11. Results of bronchoscopically obtained lower airway cultures from adult sickle cell disease patients with the acute chest syndrome
12. Bronchoalveolar lavage in adult sickle cell patients with acute chest syndrome: Value for diagnostic assessment of fat embolism
13. Rib infarcts and acute chest syndrome in sickle cell disease
14. Pulmonary fat embolism: A distinct cause of severe acute chest syndrome in sickle cell anemia
15. Causes and outcomes of the acute chest syndrome in sickle cell disease
16. Clinician assessment for acute chest syndrome in febrile patients with sickle cell disease: Is it accurate enough?
17. Sickle cell anemia, a molecular disease
18. Pathogenesis and treatment of sickle cell disease
19. Beyond hemoglobin polymerization: The red blood cell membrane and sickle disease pathophysiology
20. Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V
21. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: Flow-cytometric measurement and clinical associations
22. Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium
23. Fetal hemoglobin in sickle cell disease: Relationship to erythrocyte phosphatidylserine exposure and coagulation activation
24. Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: A potential role for platelet activation in sickle cell vaso-occlusion
25. Mechanism of interaction of thrombospondin with human endothelium and inhibition of sickle erythrocyte adhesion to human endothelial cells by heparin
26. Anionic polysaccharides inhibit adhesion of sickle erythrocytes to the vascular endothelium and result n improved hemodynamic behavior
27. Monoclonal antibodies to αVβ3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor
28. Unusually large vWF multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow
29. Sickle cell adhesion to laminin: Potential role for the α5 chain
30. Adhesive interactions of sickle erythrocytes with endothelium
31. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease
32. Tissue factor expression by endothelial cells in sickle cell anemia
33. Introduction: Anti-adhesion therapy in sickle cell disease
34. Sickle cell acute chest syndrome: Pathogenesis and rationale for treatment
35. α4β1 integrin expression on sickle erythrocytes: Vascular cell adhesion molecule-1 dependent binding to endothelium
36. Integrin α4β1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia
37. Sickle reticulocytes adhere to VCAM-1
38. Thrombospondin mediated adherence of CD36+ sickle reticulocytes to endothelial cells
39. CD36-positive stress reticulocytes in sickle cell anemia
40. Band 3 peptides block the adherence of sickle cells to endothelial cells in vitro
41. Increased adhesion of erythrocytes to components of the extracellular matrix. Isolation and characterization of a red blood cell ligand that binds thrombospondin and laminin
42. Adherence of phosphatidylserine - Exposing erythrocytes to endothelial matrix thrombospondin
43. Inhibition of plasma-mediated adherence of sickle erythrocytes to microvascular endothelium by conformationally constrained RGD-containing peptides
44. Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red cell adherence to endothelium: Potential role in sickle cell disease
45. Pathogenesis and treatment of acute chest syndrome in sickle cell anemia
46. Nitric oxide decreases cytokine-induced endothelial activation. NO selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines
47. Elevated serum levels of free fatty acids in sickle cell patients with acute chest syndrome and acute multi-organ failure syndrome
48. ARDS: Clinical lessons from oleic acid model of acute lung injury
49. Hypoxia decreases constitutive NO synthase transcript and protein in cultured endothelial cells
50. Sickle erythrocytes after sickling regulates the expression of the endothelin-1 and nitric oxide synthase genes in human endothelial cells
51. Sickle erythrocytes after sickling regulates the expression of endothelin-1 gene and protein n human endothelial cells in culture
52. Endothelin-1 production during the acute chest syndrome in sickle cell disease
53. Impaired nitric oxide-mediated vasodilation in the transgenic sickle mouse
54. Increased oxidative stress and altered nitric oxide metabolism during "acute chest syndrome" in the transgenic sickle cell mouse
55. Nitric oxide metabolite levels in acute vaso-occlusive sickle cell crisis
56. The release of nitric oxide and superoxide anion by neutrophils and mononuclear cells from patients with sickle cell disease
57. Acute chest syndrome in sickle cell disease: CT evidence of microvascular occlusion
58. Pulmonary entrapment of sickle cells: The role of regional alveolar hypoxia
59. Inhaled nitric oxide prevents neutrophil-mediated oxygen radical-dependent leak in isolated rat lungs
60. Inhaled nitric oxide prevents IL-1-induced neutrophil accumulation and associated acute edema in isolated rat lungs
61. Nitric oxide attenuates interleukin-2 induced lung injury
62. Nitric oxide: Mediator, murderer and medicine
63. Red blood cell augmentation of hypoxic pulmonary vasoconstriction: Hematocrit dependence and the importance of nitric oxide
64. The L-arginine-nitric oxide pathway
65. Case report: Aplastic crisis in sickle cell disorders. Bone marrow necrosis and human parvovirus infection
66. Sickle cell acute chest syndrome associated with parvovirus B19 infection: Case series and review
67. Potentiated adherence of sickle erythrocytes to endothelium infected by virus
68. Fat embolism, incidence at postmortem
69. Necrosis of the bone marrow with fat embolism in sickle cell disease
70. Bone marrow and fat embolism in sickle cell anemia and sickle cell hemoglobin C disease
71. Pulmonary changes in sickle cell disease
72. The lung in sickle cell disease
73. Bronchoalveolar lavage in adult sickle cell patients with acute chest syndrome: Value for diagnostic assessment of fat embolism
74. Phospholipase A2 levels in acute chest syndrome of sickle cell disease
75. Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease
76. Type 1 phospholipase A2 propeptide in acute lung injury
77. Scintigraphic evidence of pulmonary vascular occlusion in sickle cell disease
78. Rib infarcts and acute chest syndrome in sickle cell disease
79. Simultaneous occurrence of rib infarction and pulmonary infiltrates in sickle cell disease patients with acute chest syndrome
80. Incentive spirometry to prevent acute pulmonary complications in sickle cell disease
81. Acute chest syndrome in the postoperative sickle cell patient
82. Pulmonary edema complications in the management of sickle cell pain crisis
83. The acute chest syndrome of sickle cell disease
84. Inhaled nitric oxide in sickle cell disease with acute chest syndrome
85. Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent
86. Acute chest syndrome n adults with sickle cell disease. Therapeutic approach, outcome and results of BAL in a monocentric series of 107 episodes
87. Effect of transfusion in acute chest syndrome of sickle cell disease
88. Determination of hemoglobin saturation in acute chest syndrome. A comparison of arterial blood gases and pulse oximetry
89. Transfusion management of sickle cell disease
90. Successful treatment of life-threatening acute chest syndrome of sickle cell disease with venovenous extra corporeal membrane oxygenation
91. Acute respiratory distress syndrome
92. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease
93. Modulation of endothelial expression of ICAM-1, Eselectin and VCAM-1 by β-Estradiol progesterone and dexamethasone
94. Endogenous endothelium-derived relaxing factor opposes hypoxic pulmonary vasoconstriction and supports blood flow to hypoxic alveoli in anesthetized rabbits
95. The acute chest syndrome in sickle cell disease: Possible role of nitric oxide in its pathophysiology and treatment
96. Clinical approach to inhaled nitric oxide therapy in the newborn with hypoxemia
97. Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilation
98. Inhaled nitric oxide causes selective pulmonary vasodilation in patients with pulmonary hypertension
99. Inhaled nitric oxide for the adult respiratory distress syndrome
100. S-nitrosohaemoglobin, a dynamic activity of blood involved in vascular control
101. Reactions between nitric oxide and hemoglobin under physiologic conditions
102. Blood flow regulation by S-nitrosoHb in the physiological oxygen gradient
103. Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity
104. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and vivo
105. Can we just say NO to sickle cell anemia?
106. Nitric oxide in the lung: Therapeutic and cellular mechanisms of actions
107. Review: Nitric oxide in adult lung disease
108. Effect of endogenous and inhaled nitric oxide on the ventilation-perfusion relationships in oleic acid lung injury
109. Inhibition of erythrocyte sickling by thiol reagents
110. Cell-free and erythrocytic S-nitrosohemoglobin inhibits human platelet aggregation
111. Inhaled nitric oxide decreases hyperoxia-induced surfactant abnormality in preterm rabbits
112. Detection of nitrosylhemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea
113. Free radical chemistry of nitric oxide: Looking at the darkside
114. Effects of inhaled nitric oxide or inhibition of endogenous nitric oxide formation on hyperoxic lung injury
115. Apparent hydroxy radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide
116. Combined effects of nitric oxide and hyperoxia on surfactant function and pulmonary inflammation
117. Inhaled nitric oxide primes lung macrophages to produce reactive oxygen and nitrogen intermediates
118. Phase I study of Flocor in patients with acute chest syndrome of sickle cell disease
119. Flocor can prevent the development of hypoxia-induced ACS in transgenic sickle mice
120. Animal model of acute chest syndrome Demonstration of acute chest syndrome in transgenic mice that produce various levels of human HbS